Tofacitinib 5 mg Generic Availability
Tofacitinib, commonly known by the brand name Xeljanz, is a Janus kinase (JAK) inhibitor used to treat certain autoimmune conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. As of early 2024, generic versions of tofacitinib 5 mg are available in the market, following the expiration of key patents for the original drug [1][2].
When Did Tofacitinib Go Generic?
The patent exclusivity for Xeljanz began to expire in late 2022 and early 2023 in various regions, paving the way for the introduction of generic tofacitinib products. This allows for more affordable treatment options for patients [1][3].
Who Makes Generic Tofacitinib?
Multiple pharmaceutical companies have launched generic versions of tofacitinib. These include companies like Viatris, Accord Healthcare, and others that specialize in producing generic medications [1][2].
How Does Generic Tofacitinib Differ from Brand-Name Xeljanz?
Generic tofacitinib is bioequivalent to brand-name Xeljanz, meaning it contains the same active ingredient, tofacitinib, in the same dosage strength. The key difference lies in the inactive ingredients, which can vary between the generic and brand-name versions. These inactive ingredients do not affect the drug's safety or efficacy. The cost is typically significantly lower for generic medications compared to their brand-name counterparts [4].
What is the Cost of Generic Tofacitinib 5 mg?
The price of generic tofacitinib 5 mg can vary depending on the manufacturer, the pharmacy, and insurance coverage. However, it is generally substantially less expensive than Xeljanz. Patients are advised to compare prices at different pharmacies and consult with their insurance providers for the most accurate cost information [4].
What is the Difference Between Tofacitinib and Other JAK Inhibitors?
Tofacitinib belongs to a class of drugs known as Janus kinase (JAK) inhibitors. Other JAK inhibitors include upadacitinib (Rinvoq) and baricitinib (Olumiant). While they all target JAK enzymes to reduce inflammation, they may have differences in their selectivity for specific JAK enzyme subtypes, which can influence their efficacy and side effect profiles for different conditions [5].
What Are the Risks Associated with Tofacitinib?
Like all medications, tofacitinib carries potential risks. These include an increased risk of serious infections, blood clots, heart attack, stroke, and certain cancers. Patients should discuss these risks thoroughly with their healthcare provider before starting treatment [6].
Where Can I Find Information on Tofacitinib Patents?
Information regarding patents for tofacitinib, including their expiration dates and any ongoing litigation, can be found on specialized intellectual property databases. DrugPatentWatch.com provides detailed patent information on pharmaceuticals, including tofacitinib [7].
Sources:
- https://www.drugpatentwatch.com/
- https://www.drugpatentwatch.com/drug/tofacitinib/generics
- https://www.drugpatentwatch.com/drug/tofacitinib/patent-expiry
- https://www.goodrx.com/tofacitinib
- https://www.mayoclinic.org/drugs-supplements/tofacitinib-oral-capsule-oral-tablet/medical-overview/drg-20065167
- https://www.fda.gov/drugs/drug-safety-and-availability/fda-safety-communication-box-and-other-safety-label-changes-regarding-jak-inhibitors-such-as
- https://www.drugpatentwatch.com/drug/tofacitinib